Transfusion-associated graft-versus-host disease

Current Opinion in Hematology

Volumn 4, Issue 6, 1997, Pages 442-448

  Orlin, Jerome B ^a   Ellis, Martin H ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; THYMOCYTE ANTIBODY;

BLEEDING; BLOOD BANK; BLOOD TRANSFUSION; BONE MARROW APLASIA; CAUSE OF DEATH; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; FEVER; GENE LOCUS; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HOMOZYGOSITY; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKAPHERESIS; LIVER DYSFUNCTION; PATHOPHYSIOLOGY; PREMATURITY; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; ULTRAVIOLET B RADIATION;

EID: 0030817818     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704060-00015     Document Type: Review

References (54)

1. Brubaker DB: Transfusion-associated graft versus host disease. Hum Pathol 1987, 17:1085-1087.
2. Greenbaum BH: Transfusion associated graft versus host disease: historical perspectives, incidence and current use of irradiated blood products. J Clin Oncol 1991, 9:1889-1902.
3. Ohto H, Anderson K: Survey of transfusion associated graft versus host disease in immunocompetent patients. Trans Med Rev 1996, 10:31-43. This article introduces into the English literature important information regarding the clinical features and epidemiology of TA-GVHD in immunocompetent patients that has hitherto been published in Japanese only.
4. Juji T, Takahashi K, Shibata Y, Ide H, Sakakibara T, Ino T, Mori S: Post transfusion graft versus host disease in immunocompetent patients after cardiac surgery in Japan. N Engl J Med 1989, 321:56-59.
5. Shivdasani R, Anderson KC: HLA homozygosity and shared HLA haplotypes in the development of transfusion associated graft versus host disease. Leuk Lymphoma 1994, 15:227-234.
6. Ito K, Yoshida H, Yanagibashi K, Shimada Y, Imamura M, Tobe T, Akiyama Y, Saji H, Maruya E, Hosoi T: Change of HLA phenotype in postoperative erythroderma. Lancet 1988, 1:413-414.
7. Nishimura M, Uchida S, Mitsunaga S, Yahagi Y, Nakajima K, Tadokoro K, Juji T: Characterization of T-cell clones derived from peripheral blood lymphocytes of a patient with transfusion associated graft versus host disease: Fas-mediated killing by CD4+ and CD8+ cytotoxic T-cell clones and tumor necrosis factor B production by CD4+ T-cell clones. Blood 1997, 89:1440-1445. This paper demonstrates specific effector cell targets involved in the pathophysiology of TA-GVHD and discusses mechanisms of host tissue damage.
8. Nishimura M, Uchida S, Mitsunaga S, Tokunaga K, Tadokoro K, Juji T: Identification of the target molecule of cytotoxic T cells presumably responsible for development of transfusion associated graft versus host disease [letter]. Transfusion 1996, 36:846-847.
9. Braun MY, Lowin B, French L, Orbea HA, Tschopp J: Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytotoxic activity yet lose their capacity to induce lethal graft versus host disease. J Exp Med 1996, 183:657-662.
10. Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, et al.: Processing of tumor necrosis factor α precursor by metalloproteinases. Nature 1994, 370:555-558.
11. Nishimura M, Uchida S, Mitsunaga S, Tokunaga K, Tadokoro K, Juji T: Evidence of involvement of cytotoxic antibodies directed against patient's HLA class II produced by transfused donor-derived B cells in post transfusion graft versus host disease. Br J Hematol 1996, 92:1011-1013. The role of donor B cells in the pathophysiology of TA-GVHD is uncovered in this report.
12. Fast LD, Valeri CR, Crowley JP: Immune responses to major histocompatibility complex homozygous lymphoid cells in murine F1 hybrid recipients: implications for transfusion associated graft versus host disease. Blood 1995, 86:3090-3096.
13. Manno CS: What's new in transfusion medicine? Ped Clin North Am 1996, 43:793-808.
14. Beutler E, Koziol J, McMillan R, Sipe JC, Romine JS, Carrera CJ: Marrow suppression produced by repeated doses of Cladribine. Acta Hematol 1994, 91:10-15.
15. Briz M, Cabrera R, Sanjuan I, Fores R, Diez JL, Herero M, Regidor C, Algora M, Fernandez MN: Diagnosis of transfusion associated graft versus host disease by polymerase chain reaction in fludarabine treated B-chronic lymphocytic leukemia. Br J Hematol 1995, 91:409-411.
16. Zulian GB, Roux E, Tiercy JM, Extermann M, Diebold-Berger S, Reymond J-M, Helg C, Zubler R, Betticher C, Alberto P, Jeannet M, Chapuis B: Transfusion-associated graft-versus-host disease in a patient treated with Cladribine (2-chlorodeoxyadenosine): demonstration of exogenous DNA in various tissue extracts by PCR analysis. Br J Hematol 1995, 89:83-89.
17. Briones J, Pereira A, Alcorta I: Transfusion associated graft versus host disease in fludarabine treated patients: is it time to irradiate blood components? [letter]. Br J Hematol 1996, 93:739-740.
18. Sakakibara T, Juji T: Post transfusion graft versus host disease after open heart surgery [letter]. Lancet 1986, 2:1099.
19. Ferrara JLM, Deeg HJ: Graft versus host disease. N Engl J Med 1991, 324:667-674.
20. Thaler M, Shamiss A, Orgad S, Meisel S: The role of blood from HLA-homozygous donors in fatal transfusion-associated graft versus host disease. N Engl J Med 1989, 321:25-28.
21. Takahashi K, Juji T, Miyamoto M: Analysis of risk factors for post transfusion graft versus host disease in Japan: Japanese Red Cross PTGVHD study. Lancet 1994, 343:700-702.
22. Ohto H, Anderson K: Posttransfusion graft versus host disease in Japanese newborns. Transfusion 1996, 36:117-123.
23. Lavee J, Shinfeld A, Savion N, Thaler M, Mohr R, Goor DA: Irradiation of fresh whole blood for prevention of transfusion associated graft versus host disease does not impair platelet function and clinical hemostasis after open heart surgery. Vox Sang 1995, 69:104-109.
24. Takahashi K, Juji T, Miyazaki H: Post transfusion graft versus host disease occurring in non-immunosuppressed patients in Japan. Transfus Sci 1991, 12:281-289.
25. Petz L, Calhoun L, Yam P: Transfusion associated graft versus host disease on immunocompetent patients: report of a fatal case and a survey of predisposing factors. transfusion 1993, 33:742-750.
26. Santamaria P, Reinsmoen NL, Lindstrom AL: Frequent HLA class I and DP sequence mismatches in serologically and molecularly HLA-identical unrelated bone marrow transplant pairs. Blood 1994, 83:280-287.
27. Wagner FF, Flegel WA: Transfusion associated graft versus host disease: risk due to homozygous HLA haplotypes. Transfusion 1995, 35:284-291.
28. Appleton AL, Sviland L, Pearson ADJ, Wilkes J, Green MA, Malcolm AJ: Diagnostic features of transfusion associated graft versus host disease. J Clin Pathol 1994, 47:541-546.
29. Anderson K: Tansfusion associated graft versus host disease. J Clin Oncol 1991, 9:1727-1730.
30. Otsuka S, Kuneida K, Hirose M: Fatal erythroderma after cholecystectomy. Transfusion 1989, 29:544-548.
31. Wang L, Juji T, Tokunaga K, Takahashi K, Uchida S, Tadokoro K, Juji T: Polymorphic microsatellite markers for the diagnosis of graft versus host disease. N Engl J Med 1994, 330:398-401.
32. Uchida S, Wang L, Yahagi Y, Tokunaga K, Tadokoro K, Juji T: Use of fingernail DNA for evaluation of chimerism after bone marrow transplantation and for diagnostic testing for transfusion associated graft versus host disease. Blood 1996, 87:4015-4016.
33. Sanders MR, Graeber JE: Post-transfusion graft versus host disease in infancy. J Pediatr 1990, 117:159-163.
34. Luban NLC, DePalma L: Transfusion associated graft versus host disease in the neonate-extending the spectrum of disease. Transfusion 1996, 36:101-103.
35. Mori S, Matsushita H, Ozaki K, Ishida A, Tokuhira M, Nakajima H, Kizaki M, Suguira H, Kikuchi A, Handa M, et al.: Spontaneous resolution of graft versus host disease. Transfusion 1995, 35:431-435.
36. Friedman DF, Kwittken P, Cizman B, Argyris E, Kearns J, Yang SY, Zmijewski C, Bunin N, Douglas SD, Monos D: DNA-based HLA typing of nonhematopoietic tissue used to select the marrow transplant donor for successful treatment of transfusion associated graft versus host disease. Clin Diagn Lab Immunol 1994, 5:590-596.
37. Yasukawa M, Shinozaki F, Halo T, Takada K, Ishii Y, Tamai T, Takamatsu T, Shiobara S, Yoshizaki K, Fujita S: Successful treatment of transfusion associated graft versus host disease. 1994, 86:831-834.
38. Moroff JH, Luban NL: Prevention of transfusion associated graft versus host disease. Transfusion 1992, 32:879-882.
39. Hull RJ, Bray RA, Hillyer C, Swerlick RA: Transfusion associated cutaneous chronic graft versus host disease. J Am Acad Dermatol 1995, 33:327-332.
40. Hayashi H, Nischiuchi T, Tamura H, Takeda K: Transfusion associated graft versus host disease caused by leukocyte filtered stored blood. Anesthesiology 1993, 79:1419-1421.
41. Bernvil SS, Abdulaitiff M, Al-Sedairy S, Sasich F, Sheth K: Fresh frozen plasma contains viable progenitor cells-should we irradiate? [letter]. Vox Sang 1994, 67:405.
42. Przepiorka D, LeParc G, Stovall MA, Werch J, Lichtiger B: Use of irradiated blood components. Am J Clin Pathol 1996, 106:6-11. This American Society of Clinical Pathology practice guideline identifies patients who should receive irradiated blood and describes technical aspects of blood component irradiation.
43. Thomas ED, Herman EC, Greenough WB: Irradiation and marrow infusion in leukemia. Arch Intern Med 1961, 107:829-845.
44. Valerius NH, Johansen KS, Nielsen OS: Effect of in vitro X irradiation on lymphocyte and granulocyte function. Scand J Hematol 1981, 27:9-18.
45. Rosen NR, Weidner JG, Boldt HD, Rosen DS: Prevention of transfusion associated graft versus host disease: selection of an adequate dose of gamma radiation. Transfusion 1993, 33:125-127.
46. Rivet C, Baxter A, Rock G: Potassium levels in irradiated blood. Transfusion 1989, 29:185.
47. Read EJ, Kodis C, Carter CS, Leitman SF: Viability of platelets following storage in the irradiated state. Transfusion 1988, 28:446-450.
48. Anand AJ, Dzik WH, Imam A, Sadrzadeh SMH: Radiation-induced red cell damage: role of reactive oxygen species. Transfusion 1997, 37:160-165.
49. Webb DK: Irradiation in the prevention of transfusion associated graft versus host disease. Arch Dis Child 1995, 73:388-389.
50. Deeg HJ, Graham TC, Gerhard-Miller L, Appelbaum FR, Schuening F, Storb R: Prevention of transfusion induced graft versus host disease in dogs by ultraviolet irradiation. Blood 1989, 74:2592-2595.
51. Brubaker DB: Transfusion associated graft versus host disease. In Scientific Basis of Transfusion Medicine. Edited by Anderson K, Ness P. Philadelphia, WB Saunders Company; 1994:544-579.
52. Webb DKH: Preventative policies in transfusion associated graft versus host disease in the treatment of cancer. Arch Dis Child 1994, 71:532-533.
53. Anderson KC: Clinical indications for blood component irradiation. In Irradiation of Blood Components. Edited by Baldwin ML, Jeffries L. Bethesda, MD: American Association of Blood Banks; 1992:31-49.
54. Dzik WH, Jones KS: The effects of gamma irradiation versus white cell reduction on the mixed lymphocyte culture. Transfusion 1993, 33:493-496.